Hologic to use existing line of credit for Mobidiag purchase

By Sara Rosenberg

New York, April 8 – Hologic Inc. plans to use borrowings on its existing line of credit and cash on hand to fund its acquisition of Mobidiag Oy, according to a news release.

Mobidiag, a commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, is being bought for about $795 million, including a cash payment of roughly $714 million and net debt of about $81 million.

Closing is expected early in the fourth quarter of fiscal 2021, subject to regulatory approvals and other customary conditions.

Hologic is a Marlborough, Mass.-based medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.